Literature DB >> 18538481

Multi-functional nanocarriers to overcome tumor drug resistance.

Lara S Jabr-Milane1, Lilian E van Vlerken, Sunita Yadav, Mansoor M Amiji.   

Abstract

The development of resistance to variety of chemotherapeutic agents is one of the major challenges in effective cancer treatment. Tumor cells are able to generate a multi-drug resistance (MDR) phenotype due to microenvironmental selection pressures. This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors. Our own work along with evidence from the literature illustrates the development of various types of engineered nanocarriers specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies. Additionally, multi-functional nanocarriers are developed to enhance drug delivery and overcome MDR by either simultaneous or sequential delivery of resistance modulators (e.g., with P-glycoprotein substrates), agents that regulate intracellular pH, agents that lower the apoptotic threshold (e.g., with ceramide), or in combination with energy delivery (e.g., sound, heat, and light) to enhance the effectiveness of anticancer agents in refractory tumors. In preclinical studies, the use of multi-functional nanocarriers has shown significant promise in enhancing cancer therapy, especially against MDR tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18538481      PMCID: PMC2585991          DOI: 10.1016/j.ctrv.2008.04.003

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  82 in total

1.  Materials science. Watching nanoparticles grow.

Authors:  Geoff Thornton
Journal:  Science       Date:  2003-05-30       Impact factor: 47.728

2.  Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets.

Authors:  H Morjani; N Aouali; R Belhoussine; R J Veldman; T Levade; M Manfait
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

3.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck.

Authors:  M Nordsmark; M Overgaard; J Overgaard
Journal:  Radiother Oncol       Date:  1996-10       Impact factor: 6.280

4.  Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.

Authors:  Valérie Gouazé; Yong-Yu Liu; Carlton S Prickett; Jing Y Yu; Armando E Giuliano; Myles C Cabot
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

Review 5.  The hypoxic core: a possible answer to the cancer paradox.

Authors:  Michael Guppy
Journal:  Biochem Biophys Res Commun       Date:  2002-12-13       Impact factor: 3.575

6.  Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.

Authors:  Ho Lun Wong; Reina Bendayan; Andrew Mike Rauth; Xiao Yu Wu
Journal:  J Control Release       Date:  2006-09-26       Impact factor: 9.776

Review 7.  "Nano": the new nemesis of cancer.

Authors:  Shantesh Hede; Nagraj Huilgol
Journal:  J Cancer Res Ther       Date:  2006 Oct-Dec       Impact factor: 1.805

8.  Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.

Authors:  Jun Wu; Yanhui Lu; Alice Lee; Xiaogang Pan; Xiaojuan Yang; Xiaobin Zhao; Robert J Lee
Journal:  J Pharm Pharm Sci       Date:  2007       Impact factor: 2.327

Review 9.  Ceramide: physiological and pathophysiological aspects.

Authors:  Marcus Schenck; Alexander Carpinteiro; Heike Grassmé; Florian Lang; Erich Gulbins
Journal:  Arch Biochem Biophys       Date:  2007-04-11       Impact factor: 4.013

Review 10.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

View more
  83 in total

Review 1.  Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance.

Authors:  William C Zamboni; Vladimir Torchilin; Anil K Patri; Jeff Hrkach; Stephen Stern; Robert Lee; Andre Nel; Nicholas J Panaro; Piotr Grodzinski
Journal:  Clin Cancer Res       Date:  2012-06-05       Impact factor: 12.531

2.  Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro.

Authors:  Forrest M Kievit; Freddy Y Wang; Chen Fang; Hyejung Mok; Kui Wang; John R Silber; Richard G Ellenbogen; Miqin Zhang
Journal:  J Control Release       Date:  2011-01-26       Impact factor: 9.776

3.  Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line.

Authors:  Huan Meng; Monty Liong; Tian Xia; Zongxi Li; Zhaoxia Ji; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2010-08-24       Impact factor: 15.881

4.  Paclitaxel nanocrystals for overcoming multidrug resistance in cancer.

Authors:  Yang Liu; Leaf Huang; Feng Liu
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

5.  Block copolymer micelles with acid-labile ortho ester side-chains: Synthesis, characterization, and enhanced drug delivery to human glioma cells.

Authors:  Rupei Tang; Weihang Ji; David Panus; R Noelle Palumbo; Chun Wang
Journal:  J Control Release       Date:  2010-12-29       Impact factor: 9.776

Review 6.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Authors:  Lara Milane; Shanthi Ganesh; Shruti Shah; Zhen-Feng Duan; Mansoor Amiji
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

Review 7.  Strategies to target tumors using nanodelivery systems based on biodegradable polymers, aspects of intellectual property, and market.

Authors:  Michele F Oliveira; Pedro P G Guimarães; Alinne D M Gomes; Diego Suárez; Rubén D Sinisterra
Journal:  J Chem Biol       Date:  2012-11-30

Review 8.  Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer.

Authors:  Daniel C Julien; Steven Behnke; Guankui Wang; Gordon K Murdoch; Rodney A Hill
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

9.  Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug-gene co-delivery to cancer cells.

Authors:  Chih-Kuang Chen; Wing-Cheung Law; Ravikumar Aalinkeel; Yun Yu; Bindukumar Nair; Jincheng Wu; Supriya Mahajan; Jessica L Reynolds; Yukun Li; Cheng Kee Lai; Emmanuel S Tzanakakis; Stanley A Schwartz; Paras N Prasad; Chong Cheng
Journal:  Nanoscale       Date:  2014       Impact factor: 7.790

Review 10.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.